Dianthus Therapeutics, Inc. (DNTH) Stock: Price, Forecast & Analyst Target
Dianthus Therapeutics, Inc. (DNTH) — MoonshotScore 30/100 (Weak band), calculated Oct 4, 2026. Price $88.21 (-0.12%), as of the Oct 2, 2026 trading session; market cap $4.93B. Expected results Nov 5, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 5.56× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 5, 2026
Dianthus Therapeutics, Inc. · DNTH · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune disease, with lead candidates in active development. The investment case depends on whether candidates can progress through clinical trials to approval and market adoption before the company's cash reserve diminishes.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Dianthus Therapeutics (DNTH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.
- quarterly revenue $761,000 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 72.05 · Piotroski F 1
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak |
The score moved from 25 in the stored Oct 3, 2026 snapshot to 30 in the current publication computed Oct 4, 2026 (+5); the largest pillar moves were Momentum -12.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $88.21 | |
| Change on the day | -0.12% | |
| 52-week range | $32.22 – $117.88 | |
| Market capitalisation | $4.93B | |
| Shares traded on the day | 751.4K | |
| Beta (volatility vs the S&P 500) | 0.08 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Dianthus Therapeutics (DNTH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the DNTH film — every key number, told as a short cinematic story
~2 min · open the film
What is Dianthus Therapeutics (DNTH), and what does it report?
Short answer · as of
Dianthus does not yet have an approved product or significant revenue.
Research dated 2026-09-13.
Dianthus does not yet have an approved product or significant revenue. The company's reporting shows the classic clinical-stage biotech profile: minimal revenue from a licensing agreement, and operating losses driven entirely by research and development spending. The lead clinical candidate, claseprubart, is a monoclonal antibody engineered to target the active form of the complement protein with extended half-life and high selectivity, addressing complement-mediated inflammation in severe autoimmune conditions.
A second candidate targets plasmacytoid dendritic cells to suppress interferon production and suppress B cell function. Both are designed for conditions where few alternatives exist, which typically supports higher prices if approved.
What do the latest results show for Dianthus Therapeutics (DNTH)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $761,000.
Research dated 2026-09-13.
The most recent quarter showed the highest cash burn rate the company has recorded. Research and development spending climbed sharply while revenue remained minimal and unstable, driven by the small licensing agreement with no growth visible in the near term. This acceleration reflects the company's movement deeper into clinical development, which is expected to become even more capital-intensive as trials expand.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $761,000 Jun 30, 2026
- Latest quarter · R&D
- $48.69M Jun 30, 2026
- Latest quarter · SG&A
- $13.56M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$61.48M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $761,000 | $48.69M | $13.56M | −$61.48M |
| Mar 31, 2026 | $463,000 | $34.53M | $12.47M | −$46.53M |
| Dec 31, 2025 | $284,000 | $59.90M | $9.93M | −$69.54M |
| Sep 30, 2025 | $396,000 | $32.49M | $8.20M | −$40.29M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $761,000 Aug 4, 2026
- Latest report · revenue estimate
- $297,182 Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $761,000 | $297,182 | −$0.9000 | −$0.8463 |
| May 5, 2026 | $463,000 | $403,615 | −$0.8500 | −$1.1700 |
| Mar 9, 2026 | $284,000 | $552,231 | −$1.4300 | −$0.9800 |
| Nov 5, 2025 | $396,000 | $576,000 | −$0.9700 | −$0.8600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $761,000 | -$50M | -$0.90 (diluted) |
| Q1 FY2026 | $463,000 | -$41M | -$0.85 (diluted) |
| Q4 FY2025 | $284,000 | $98M | $2.59 (diluted) |
| Q3 FY2025 | $396,000 | -$37M | -$0.97 (diluted) |
What are the financial strengths and risks for Dianthus Therapeutics (DNTH)?
Short answer
Cash and short-term investments were $886.81M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$48.98M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The company's major strength is the absolute scale of its cash reserve relative to the quarterly burn rate, which covers the projected timeline through the expected approval decision. Debt is nearly nonexistent, leaving cash as the only material liability. The central risk is the clinical and commercial success of the lead candidates; a failure in trials or poor market uptake would eliminate substantially all shareholder value. A secondary risk is that the burn rate will accelerate further or that the timeline to approval will extend, eroding the margin of safety that the current reserve provides.
Data-derived red flags
- Negative return on equity (-3.5%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$48.98M Jun 30, 2026
- Previous quarter · operating cash flow
- −$28.86M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$48.98M | −$180,000 |
| Mar 31, 2026 | −$28.86M | −$10,000 |
| Dec 31, 2025 | −$46.98M | −$140,000 |
| Sep 30, 2025 | −$30.55M | $0.00 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Dianthus Therapeutics (DNTH)?
Short answer · as of
The next earnings report is expected on Nov 5, 2026.
Research dated 2026-09-13.
Watch for clinical trial progression updates on leading candidates. The path to profitability requires approval and market adoption of the lead programs. Management's ability to preserve cash and extend runway through the approval decision is critical; any substantial deviation from the projected burn rate should trigger reassessment.
How does Dianthus Therapeutics compare with its peers?
Short answer
Dianthus Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Dianthus differs from stable pharmaceutical companies because it has no approved products and minimal revenue. It resembles other clinical-stage immunology companies in that its value is entirely contingent on clinical success. The focus on severe autoimmune indications narrows the addressable market compared to companies pursuing broader conditions, but the unmet medical need typically supports higher prices upon approval.
| Company | Price | Market value | Score |
|---|---|---|---|
| $919.21 Oct 2, 2026 | $57.2B | 97 5-pillar Oct 4, 2026 | |
| $541.70 Oct 2, 2026 | $23.0B | 97 5-pillar Oct 4, 2026 | |
| $302.96 Oct 2, 2026 | $6.07B | 96 5-pillar Oct 4, 2026 | |
| $45.81 Oct 2, 2026 | $3.66B | 96 5-pillar Oct 4, 2026 | |
| $256.03 Oct 2, 2026 | $617B | 90 5-pillar Oct 4, 2026 | |
| $25.16 Oct 2, 2026 | $3.15B | 88 5-pillar Oct 4, 2026 | |
| $19.95 Oct 2, 2026 | $3.42B | 76 5-pillar Oct 4, 2026 | |
| $46.97 Oct 2, 2026 | $3.36B | 74 5-pillar Oct 4, 2026 | |
| $159.56 Oct 2, 2026 | $6.40B | 69 5-pillar Oct 4, 2026 | |
| $84.52 Oct 2, 2026 | $5.10B | 68 5-pillar Oct 4, 2026 | |
| $41.40 Oct 2, 2026 | $4.45B | 66 5-pillar Oct 4, 2026 | |
| $27.79 Oct 2, 2026 | $3.09B | 66 5-pillar Oct 4, 2026 | |
| Dianthus Therapeutics (DNTH) — this page | $88.21 | $4.93B | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $98.00 – $158.00
- Consensus target
- $126.83
- Median target
- $126.50
Consensus record · Captured .
Measured against a quoted price of $88.21 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026
- Transactions
- 89
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 40
- Other transactions
- 49
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 279 Period end Jun 30, 2026
- Previous quarter · holders
- 250 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 8,199,893 |
| Blackrock, INC. | 4,123,822 |
| T. Rowe Price Investment Management, INC. | 3,888,456 |
| Wellington Management Group Llp | 3,229,882 |
| Fairmount Funds Management LLC | 2,537,191 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Dianthus Therapeutics (DNTH)?
DNTH Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What complement blockade program is Dianthus advancing?
The lead program blocks the active form of the complement protein, designed to suppress complement-driven inflammation in severe autoimmune conditions. A bifunctional fusion protein works through a distinct mechanism, suppressing interferon production and B cell activity. Both address indications with substantial unmet need; the company's rising research spending reflects the development intensity required, and analyst estimates for future revenue reflect expectations of clinical success.
How long can the company operate with its current cash and burn rate?
The company's cash reserve, when divided by the current quarterly operating cash consumption, extends the runway to a date well into the projected conclusion of clinical trials. If trials take longer or burn accelerates, this timeline shortens.
Why have insiders been selling shares?
Form filings show significant insider selling in recent periods from company leadership, with no offsetting purchases. Form data records only the transaction, not the reason, but such sales often reflect vesting taxation rather than loss of confidence. Analyst coverage remains uniformly positive despite this selling pattern, providing context to interpret the activity.
What do analysts expect for future revenue?
Analyst consensus projects minimal revenue in the near term, reflecting the expectation that the lead candidates remain in trials. Revenue estimates then expand significantly in the out years, conditional on regulatory approval and market uptake. The wide range between high and low estimates reflects the inherent uncertainty of clinical-stage biotech.
What is the DNTH stock price today?
The last price recorded on this page for Dianthus Therapeutics, Inc. (DNTH) is $88.21, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DNTH price target?
The analyst consensus price target for Dianthus Therapeutics, Inc. (DNTH) is $126.83 (range $98.00 to $158.00, median $126.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 7 Times Square, 43RD Floor, NEW York, NY, 10036 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "7 Times Square, New York, NY, 10036, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 5, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $88.21 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:56.236Z. | |
px.change | Change on the day | -0.12% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $4.93B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:54.993Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.11 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $761,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 751.4K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.08 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Marino Garcia | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 92 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $1.48M, net result −$13.11M; FY2022 revenue $6.42M, net result −$28.48M; FY2023 revenue $2.83M, net result −$43.55M; FY2024 revenue $6.24M, net result −$84.97M; FY2025 revenue $2.04M, net result −$162.34M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | License $2.04M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 96.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $761,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $48.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $13.56M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$61.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $463,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $34.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $12.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$46.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $284,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $59.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $9.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$69.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $396,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $32.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $8.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$40.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $761,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $297,182 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | −$0.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | −$0.8463 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $463,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $403,615 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | −$0.8500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | −$1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-09.revenue_actual | Revenue · reported — report date 2026-03-09 | $284,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-09.revenue_estimated | Revenue · estimate — report date 2026-03-09 | $552,231 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-09.eps_actual | EPS · reported — report date 2026-03-09 | −$1.4300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-09.eps_estimated | EPS · estimate — report date 2026-03-09 | −$0.9800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $396,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $576,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | −$0.9700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | −$0.8600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $886.81M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$48.98M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $303.63M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.29M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.22× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$48.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$28.86M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$180,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$46.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$140,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$30.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $98.00 – $158.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $126.83 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $126.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 89 transactions · 0 purchases, 40 sales, 49 other transactions · 12 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 279 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 250 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 8,199,893 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 4,123,822 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 3,888,456 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Wellington Management Group Llp — shares in provider snapshot | 3,229,882 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Fairmount Funds Management LLC — shares in provider snapshot | 2,537,191 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 72.05 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
px.range52 | 52-week range | $32.22 – $117.88 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -3.5% · ROA -2.5% · current ratio 26.10 · earnings yield -0.6% · free-cash-flow yield -3.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 5.56× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $886.81M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($761,000) with the recorded estimate ($297,182) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.9000) with the recorded estimate (−$0.8463) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 30 of 100 · Weak · pillars 35 / 80 / 47 / 9 / 74 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 25 (stored snapshot Oct 3, 2026) → 30 (current publication computed Oct 4, 2026) (+5) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-03-09.revenue_actual,earn.history.depth.2026-03-09.revenue_estimated,earn.history.depth.2026-03-09.eps_actual,earn.history.depth.2026-03-09.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash, investments and debt | Total debt: $1.29M; Liquidity basis: cash and short-term investments; Total liabilities: $41.25M; Cash and short-term investments: $886.81M; Cash and investments: $1.19B; Long-term investments: $303.63M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Employees | Count: 92 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 6.9; Method: cash and short-term investments of $886.8M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($128M per year); Reaches: 2033-05; Cash basis: cash and short-term investments; Cash: $886.80M; Annualized cash use: $128.00M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Trailing twelve-month ratio set | Quick ratio: 26.1; Current ratio: 26.1; Debt to equity: 0; Net margin: -1,570.9%; Gross margin: 96%; Return on assets: -2.5%; Return on equity: -3.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | License: $2.04M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Insider transactions, last 180 days | Net shares: -299,961; Window days: 180; Price low: $8.44; Clustered days: 2026-08-10; Price high: $117.55; Buy transactions: 0; Distinct insiders: 6; Sell transactions: 30; Other transactions: 30; Total transactions: 60; Other transaction types: M-Exempt: 30; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-01 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Named officers | CEO: Marino Garcia; Officers: Adam Veness — Title: Senior Vice President, General Counsel & Secretary, Born: 1986; Edward G. Carr — Title: Senior VP & Chief Accounting Officer, Born: 1969; Judson Taylor — Title: Senior Vice President & Head of Technical Operations; Ryan Savitz — Title: Executive VP, CFO, Chief Business Officer & Treasurer, Pay: $786,096, Born: 1989; Jennifer Davis Ruff — Title: Vice President and Head of Investor Relations & Corporate Affairs.; Simrat Randhawa — Title: Executive Vice President and Head of R&D, Pay: $932,680, Born: 1970; Marino Garcia — Title: President, Chief Executive Officer & Director, Pay: $1.16M, Born: 1966; Rashieda Gluck — Title: Head of Clinical Development Operations Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-06 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Next earnings report | Date: 2026-11-05; EPS estimate: -$0.95032 per share; Revenue estimate: $443,851 The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.